|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li L and Wang H: Heterogeneity of liver
cancer and personalized therapy. Cancer Lett. 379:191–197. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Batista PJ and Chang HY: Long noncoding
RNAs: Cellular address codes in development and disease. Cell.
152:1298–1307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guttman M and Rinn JL: Modular regulatory
principles of large non-coding RNAs. Nature. 482:339–346. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wapinski O and Chang HY: Long noncoding
RNAs and human disease. Trends Cell Biol. 21:354–361. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Geisler S and Coller J: RNA in unexpected
places: Long non-coding RNA functions in diverse cellular contexts.
Nat Rev Mol Cell Biol. 14:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Y, Chen L, Gu J, Zhang H, Yuan J,
Lian Q, Lv G, Wang S, Wu Y, Yang YT, et al: Recurrently deregulated
lncRNAs in hepatocellular carcinoma. Nat Commun. 8:144212017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esposti DD, Hernandez-Vargas H, Voegele C,
Fernandez-Jimenez N, Forey N, Bancel B, Le Calvez-Kelm F, McKay J,
Merle P and Herceg Z: Identification of novel long non-coding RNAs
deregulated in hepatocellular carcinoma using RNA-sequencing.
Oncotarget. 7:31862–31877. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cui H, Zhang Y, Zhang Q, Chen W, Zhao H
and Liang J: A comprehensive genome-wide analysis of long noncoding
RNA expression profile in hepatocellular carcinoma. Cancer Med.
6:2932–2941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seitz H, Youngson N, Lin S, Dalbert S,
Paulsen M, Bachellerie JP, Ferguson-Smith AC and Cavaille J:
Imprinted microRNA genes transcribed antisense to a reciprocally
imprinted retrotransposon-like gene. Nat Genet. 34:261–262. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo J, Qu J, Wu DK, Lu ZL, Sun YS and Qu
Q: Long non-coding RNAs: A rising biotarget in colorectal cancer.
Oncotarget. 8:22187–22202. 2017.PubMed/NCBI
|
|
15
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: ceRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu C and Lin J: Long noncoding RNA
ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically
activating ZEB1. Am J Transl Res. 8:4095–4105. 2016.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang K, Liu CY, Zhou LY, Wang JX, Wang M,
Zhao B, Zhao WK, Xu SJ, Fan LH, Zhang XJ, et al: APF lncRNA
regulates autophagy and myocardial infarction by targeting
miR-188-3p. Nat Commun. 6:67792015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li M, Yang Y, Kuang Y, Gan X, Zeng W, Liu
Y and Guan H: miR-365 induces hepatocellular carcinoma cell
apoptosis through targeting Bcl-2. Exp Ther Med. 13:2279–2285.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li J, Li Z, Leng K, Xu Y, Ji D, Huang L,
Cui Y and Jiang X: ZEB1-AS1: A crucial cancer-related long
non-coding RNA. Cell Prolif. 51:e124232018. View Article : Google Scholar
|
|
21
|
Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z,
Deng X, Chen H, Shen B, Peng C, et al: Upregulation of long
noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor
prognosis in hepatocellular carcinoma. Oncogene. 35:1575–1584.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lv QL, Hu L, Chen SH, Sun B, Fu ML, Qin
CZ, Qu Q, Wang GH, He CJ and Zhou HH: A long noncoding RNA ZEB1-AS1
promotes tumorigenesis and predicts poor prognosis in glioma. Int J
Mol Sci. 17:E14312016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang YL, Bai Y, Yao WJ, Guo L and Wang ZM:
Expression of long non-coding RNA ZEB1-AS1 in esophageal squamous
cell carcinoma and its correlation with tumor progression and
patient survival. Int J Clin Exp Pathol. 8:11871–11876.
2015.PubMed/NCBI
|
|
24
|
Xiong WC, Han N, Wu N, Zhao KL, Han C,
Wang HX, Ping GF, Zheng PF, Feng H, Qin L and He P: Interplay
between long noncoding RNA ZEB1-AS1 and miR-101/ZEB1 axis regulates
proliferation and migration of colorectal cancer cells. Am J Transl
Res. 10:605–617. 2018.PubMed/NCBI
|
|
25
|
Ni Y, Fang J, Zhu L, Jiang H, Liu Y, Miao
R, Shao C and Shao S: The significant prognostic value of ZEB1-AS1
up-regulation in patients with cancer. J Cancer. 9:2502–2509. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Xu C, Wang Y and Zhang X:
MicroRNA-365 inhibits ovarian cancer progression by targeting
Wnt5a. Am J Cancer Res. 7:1096–1106. 2017.PubMed/NCBI
|
|
27
|
Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y,
Du X and Han W: microRNA-365, down-regulated in colon cancer,
inhibits cell cycle progression and promotes apoptosis of colon
cancer cells by probably targeting Cyclin D1 and Bcl-2.
Carcinogenesis. 33:220–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen HZ, Tsai SY and Leone G: Emerging
roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev
Cancer. 9:785–797. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reimer D, Sadr S, Wiedemair A, Goebel G,
Concin N, Hofstetter G, Marth C and Zeimet AG: Expression of the
E2F family of transcription factors and its clinical relevance in
ovarian cancer. Ann N Y Acad Sci. 1091:270–281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Zhang X, Liu Y, Ni Z, Lin Y, Duan
Z, Shi Y, Wang G and Li F: Downregulated miR-31 level associates
with poor prognosis of gastric cancer and its restoration
suppresses tumor cell malignant phenotypes by inhibiting E2F2.
Oncotarget. 7:36577–36589. 2016.PubMed/NCBI
|
|
31
|
Nguyen-Vu T, Vedin LL, Liu K, Jonsson P,
Lin JZ, Candelaria NR, Candelaria LP, Addanki S, Williams C,
Gustafsson JA, et al: Liver × receptor ligands disrupt breast
cancer cell proliferation through an E2F-mediated mechanism. Breast
Cancer Res. 15:R512013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen L, Yu JH, Lu ZH and Zhang W: E2F2
induction in related to cell proliferation and poor prognosis in
non-small cell lung carcinoma. Int J Clin Exp Pathol.
8:10545–10554. 2015.PubMed/NCBI
|
|
33
|
Zhan L, Huang C, Meng XM, Song Y, Wu XQ,
Miu CG, Zhan XS and Li J: Promising roles of mammalian E2Fs in
hepatocellular carcinoma. Cell Signal. 26:1075–1081. 2014.
View Article : Google Scholar : PubMed/NCBI
|
